The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies
Abstract
Background: There is a lack of scientific consensus about cancer comorbidity in people with central nervous system (CNS) disorders. This study assesses the co-occurrence of cancers in patients with CNS disorders, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), autism spectrum disorders, Down's syndrome (DS), Huntington's disease (HD), multiple sclerosis (MS), Parkinson's disease (PD) and schizophrenia (SCZ). Method: Comprehensive search in PubMed/MEDLINE, Scopus and ISI Web of Knowledge of the literature published before March 2013. We identified 51 relevant articles from 2,229 discrete references, 50 of which contained data suitable for quantitative synthesis (577,013 participants). Pooled effect sizes (ES) were calculated using multiple random-effects meta-analyses. Sources of heterogeneity and uncertainty were explored by means of subgroup and sensitivity analyses, respectively. Results: The presence of CNS disorders was associated with a reduced co-occurrence of cancer (ES = 0.92; 95% confidence interval, CI: 0.87-0.98; I 2 = 94.5%). A consistently lower overall co-occurrence of cancer was detected in patients with neurodegenerative disorders (ES = 0.80; 95% CI: 0.75- 0.86; I 2 = 82.8%), and in those with AD (ES = 0.32; 95% CI: 0.22-0.46; I 2 = 0.0%), PD (ES = 0.83; 95% CI: 0.76-0.91; I 2 = 80.0%), MS (ES = 0.91; 95% CI: 0.87-0.95; I 2 = 30.3%) and HD (ES = 0.53; 95% CI: 0.42-0.67; I 2 = 56.4%). Patients with DS had a higher overall co-occurrence of cancer (ES = 1.46; 95% CI: 1.08-1.96; I 2 = 87.9%). No association was observed between cancer and ALS (ES = 0.97; 95% CI: 0.76-1.25; I 2 = 0.0%) or SCZ (ES = 0.98; 95% CI: 0.90-1.07; I 2 = 96.3%). Patients with PD, MS and SCZ showed (a) higher co-occurrence of some specific cancers (e.g. PD with melanoma, MS with brain cancers and SCZ with breast cancer), and (b) lower co-occurrence of other specific cancers (e.g. lung, prostate and colorectal cancers in PD; lung and prostate cancers in MS; and melanoma and prostate cancer in SCZ). Conclusion: Increased and decreased co-occurrence of cancer in patients with CNS disorders represents an opportunity to discover biological and non-biological connections between these complex disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Self-citationMurray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Self-citationBarnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Sterne, J. A., Egger, M., & Moher, D. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch10 · Cited by 651
Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050599 · Cited by 619
Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study
Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., Kiel, D. P., Lu, K. P., Seshadri, S., & Wolf, P. A. (2012) · BMJ · doi:10.1136/bmj.e1442 · Cited by 425 · cited 1×
“Author and year ES % weight (D + L) AD Roe et al., 2005 [23] 0.39 (0.21, 0.74) 0.69 Roe et al., 2010 [24] 0.31 (0.12, 0.86) 0.33 Driver et al., 2012 [7] 0.29 (0.18, 0.47) 1.02 Subtotal (I2 = 0.0%, p = 0.76) 0.32 (0.22, 0.46) 2.04 PD Jansson and Jankovic, 1985 [25] 0.43 (0.23, 0.63) 0.96 Møller et…”
InfluentialIncidence of Cancer Among Persons With Schizophrenia and Their Relatives
Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., & Lönnqvist, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.573 · Cited by 292 · cited 4×
“Lichtermann et al., 2001 [48] 0.88 (0.63, 1.22) 15.18 Barak et al., 2005 [49] 0.20 (0.00, 1.09) 0.58 Dalton et al., 2005 [51] 0.76 (0.52, 1.10) 14.30 Grinshpoon et al., 2005 [50] 0.77 (0.58, 1.03) 16.02 Goldacre et al., 2005 [52] 0.74 (0.44, 1.25) 11.28 Lin et al., 2013 [54] 1.44 (0.65, 3.18) 7.29…”
InfluentialTabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244
Self-citationRisk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study
Hippisley-Cox, J., Vinogradova, Y., Coupland, C., & Parker, C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.12.1368 · Cited by 214 · cited 2×
“…et al., 2005 [51] 0.96 (0.81, 1.14) 7.79 Grinshpoon et al., 2005 [50] 1.27 (1.06, 1.51) 7.76 Goldacre et al., 2005 [52] 1.18 (0.95, 1.47) 7.60 Hippisley-Cox et al., 2007 [62] 0.53 (0.34, 0.85) 6.28 Chou et al., 2011 [53] 0.55 (0.44, 0.69) 7.57 Lin et al., 2013 [54] 0.93 (0.67, 1.26) 7.12 Ji…”
Influential
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Network biology concepts in complex disease comorbidities
Hu, J. X., Thomas, C. E., & Brunak, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.87 · Cited by 328
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
Wang, M.-D., Little, J., Gomes, J., Cashman, N. R., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2016.06.015 · Cited by 269
Lanni, C., Masi, M., Racchi, M., & Govoni, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0760-2 · Cited by 130
Association of cancer and Alzheimer's disease risk in a national cohort of veterans
Frain, L., Swanson, D., Cho, K., Gagnon, D., Lu, K. P., Betensky, R. A., & Driver, J. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.04.012 · Cited by 115
Mood and Anxiety Disorders as Early Manifestations of Medical Illness: A Systematic Review
Cosci, F., Fava, G. A., & Sonino, N. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000367913 · Cited by 109
Salemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease
Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32
Metadata
- Authors
- Catalá-López, F., Suárez-Pinilla, M., Suárez-Pinilla, P., Valderas, J. M., Gómez-Beneyto, M., Martinez, S., Balanzá-Martínez, V., Climent, J., Valencia, A., McGrath, J., Crespo-Facorro, B., Sanchez-Moreno, J., Vieta, E., & Tabarés-Seisdedos, R.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 83
- Issue
- 2
- Pages
- 89-105
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1963757800
- Cited by
- 200
- References
- 17
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.